Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis

Journal of Clinical Oncology

Volumn 23, Issue 32, 2005, Pages 8253-8261

  Scher, Howard I ^a   Sawyers, Charles L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANSAMYCIN DERIVATIVE; ANTIANDROGEN; ARYLBUTYRIC ACID DERIVATIVE; BICALUTAMIDE; DIETHYLSTILBESTROL; DOCETAXEL; EVEROLIMUS; FINASTERIDE; FLUTAMIDE; FULVESTRANT; GELDANAMYCIN; GONADORELIN; HISTONE DEACETYLASE INHIBITOR; HYDROCORTISONE; KETOCONAZOLE; MEGESTROL ACETATE; MESSENGER RNA; NILUTAMIDE; STEROID 17ALPHA MONOOXYGENASE; STEROID 5ALPHA REDUCTASE INHIBITOR; VORINOSTAT;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER RESISTANCE; CANCER SURGERY; CASTRATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; DISEASE COURSE; DRUG ANTAGONISM; MALE; METABOLISM; ORCHIECTOMY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

DISEASE PROGRESSION; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 33644675811     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.4777     Document Type: Review

References (125)

1. Scher HI, Heller G: Clinical states in prostate cancer: Towards a dynamic model of disease progression. Urology 55:323-327, 2000
2. Goldenberg SL, Bruchovsky N, Rennie PS, et al: The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol 138: 1460-1465, 1988
3. Shah RB, Mehra R, Chinnaiyan AM, et al: Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 64:9209-9216, 2004
4. Buchanan G, Greenberg NM, Scher HI, et al: Collocation of androgen receptor gene mutations in prostate cancer. Clinical Cancer Res 7:1273-1281, 2001
5. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
6. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004
7. Agus DB, Cordon-Cardo C, Fox W, et al: Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 91: 1869-1876, 1999
8. Isaacs JT, Coffey DS: Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 41:5070-5074, 1981
9. Sirotnak FM, She Y, Khokhar NZ, et al: Microarray analysis of prostate cancer progression to reduced androgen dependence: Studies in unique models contrasts early and late molecular events. Mol Carcinog 41:150-163, 2004
10. Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 149:607-609, 1993
11. Wirth MP, Froschermaier SE: The antiandrogen withdrawal syndrome. Urol Res 25:S67-S71, 1997 (suppl 2)
12. Small EJ, Baron AD, Fippin L, et al: Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157:1204-1207, 1997
13. Scher HI, Buchanan G, Gerald W, et al: Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11:459-476, 2004
14. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
15. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052-1056, 2001
16. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
17. Signoretti S, Montiroini R, Manola J, et al: Her-2-neu expression and progression toward independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925, 2000
18. Osman I, Scher H, Drobnjak M, et al: HER-2/neu (p185) protein expression in the natural and treated history of prostate cancer. Clin Cancer Res 7:2643-2647, 2001
19. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470, 2003
20. Mathew P, Thall PF, Jones D, et al: Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 22:3323-3329, 2004
21. Knudsen BS, Edlund M: Prostate cancer and the MET hepatocyte growth factor receptor. Adv Cancer Res 91:31-67, 2004
22. Cairns P, Okami K, Halachmi S, et al: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997-5000, 1997
23. Vlietstra RJ, van Alewijk DC, Hermans KG, et al: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723, 1998
24. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501, 2002
25. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687-1697, 2001
26. Feldman BJ, Feldman D: The development of androgen independent prostate cancer. Nat Rev Cancer 1:34-45, 2001
27. Berger R, Febbo PG, Majumder PK, et al: Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 64:8867-8875, 2004
28. Chen CD, Welsbie DS, Tran C, et al: Molecular determinants of resistance to anti-androgen therapy. Nat Med 10:33-39, 2004
29. Han G, Buchanan G, Ittmann M, et al: Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A 102:1151-1156, 2005
30. Debes JD, Comuzzi B, Schmidt LJ, et al: p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65:5965-5973, 2005
31. Tilley WD, Buchanan G, Coetzee GA: Androgen receptor signaling in prostate cancer, in Henderson BE, Ponder BA, Ross RK (eds): Hormones Genes and Cancer. New York, NY, Oxford University Press, 2003, pp 288-315
32. Geller J: Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma. Urol Clin North Am 18:83-91, 1991
33. Labrie F, Dupont A, Belanger A, et al: New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. Prostate 4:579-594, 1983
34. Trachtenberg J, Pont A: Ketoconazole therapy for advanced prostate cancer. Lancet 2: 433-435, 1984
35. Harnett PR, Raghavan D, Caterson I, et al: Aminoglutethimide in advanced prostatic carcinoma. Br J Urol 59:323-327, 1987
36. Mohler JL, Gregory CW, Ford OH, 3rd et al: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440-448, 2004
37. Titus MA, Schell MJ, Lih FB, et al: Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653-4657, 2005
38. Labrie F, Dupont A, Simard J, et al: Intracrinology: The basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 24:94-105, 1993
39. Holzbeierlein J, Lal P, LaTulippe E, et al: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227, 2004
40. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 17:3461-3467, 1999
41. Bubendorf L, Kononen J, Koivisto P, et al: Survey of gene amplifications during prostate cancer progression by high-throughout flurorescence in situ hybridization on tissue microarrays. Cancer Res 59:803-806, 1999
42. Koivisto P, Visakorpi T, Kallioniemi OP: Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226:57-63, 1996
43. Linja MJ, Savinainen KJ, Saramaki OR, et al: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555, 2001
44. Gregory CW, Hamil KG, Kim D, et al: Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724, 1998
45. Presnell SC, Werdin ES, Maygarden S, et al: Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 159: 855-860, 2001
46. Gregory CW, Johnson RT, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898, 2001
47. Buchanan G, Irvine RA, Cotzee GA, et al: Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastatic Rev 20:207-223, 2001
48. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer 71:2574-2580, 1993
49. Pertschuk LP, Schaeffer H, Feldman JG, et al: Immunostaining for prostate cancer androgen receptor in parrafin identifies a subset of men with a poor prognosis. Lab Invest 73:302-305, 1995
50. Culig Z, Hobisch A, Hittmair A, et al: Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 35:63-70, 1998
51. Gelmann EP: Molecular biology of tne androgen receptor. J Clin Oncol 20:3001-3015, 2002
52. Buchanan G, Yang M, Harris JM, et al: Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased tansactivation function. Mol Endocrinol 15:46-56, 2000
53. Gottlieb B, Beitel LK, Wu JH, et al: The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23:527-533, 2004
54. Fenton MA, Shuster TD, Fertig AM, et al: Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 8:1383-1388. 1997
55. Taplin ME, Bubley GJ, Ko YJ, et al: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515, 1999
56. Scher HI, Liebertz C, Kelly WK, et al: Bicalutamide for advanced prostate cancer: The natural vs. treated history of disease. J Clin Oncol 15:2928-2938, 1997
57. Joyce R, Fenton MA, Rode P, et al: High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 159:149-153, 1998
58. Kassouf W, Tanguay S, Aprikian AG: Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 169:1742-1744, 2003
59. Wang L, Hsu CL, Chang C: Androgen receptor corepressors: An overview. Prostate 63:117-130, 2005
60. Yeh S. Miyamoto H, Shima H, et al: From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A 95:5527-5532, 1998
61. Yen S, Kang HY, Miyamoto H, et al. Differential induction of androgen receptor trans-activation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11:195-202, 1999
62. Gregory CW, He B, Johnson RT, et al: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319, 2001
63. Berrevoets CA, Umar A, Trapman J, et al. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor corepressor (N-CoR). Biochem J 379:731-738, 2004
64. Hodgson MC, Astapova I, Cheng S, et al: The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 280:6511-6519, 2005
65. Kang Z, Janne OA, Palvimo JJ: Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 18:2633-2648, 2004
66. Craft N, Shostak Y, Carey M, et al: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285, 1999
67. Morris MJ, Reuter VE, Kelly WK, et al: HER-2 profiling and targeting in prostate carcinoma. Cancer 94:980-986, 2002
68. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478, 1994
69. Yeh S, Lin HK, Kang HY, et al: From HER2/ Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96:5458-5463, 1999
70. Ueda T, Bruchovsky N, Sadar MD: Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 277:7076-7085, 2002
71. Gregory CW, Fei X, Ponguta LA, et al: Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119-7130, 2004
72. Wen Y, Hu MC, Makino K, et al: HER-2/ neu promotes androgen-independent survival and growth of prostate cancer cells through the AKT pathway. Cancer Res 60:6841-6845, 2000
73. Mellinghoff IK, Vivanco I, Kwon A, et al: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527, 2004
74. Kolvenbag GJ, Blackledge GR, Gotting-Smith K: Bicalutamide (CasodexR) in the treatment of prostate cancer: History of clinical development. Prostate 34:61-72, 1998
75. Fleshner N, Fair WR: Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol 78:907-910, 1996
76. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546-2550, 1986
77. Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45:839-45, 1995
78. Scher HI, Kelly WK: The flutamide with drawal syndrome: Its impact on clinical trials in hormone-refractory prostatic cancer. J Clin Oncol 11:1566-1572, 1993
79. Nieh PT: Withdrawal phenomenon with the antiandrogen casodex. J Urol 153:1070-1072, 1995
80. Kelly WK, Slovin S, Scher HI: Steroid hormone withdrawal syndromes: Pathophysiology and clinical significance. Urol Clin North Am 24:421-433, 1997
81. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer 76:1428-1434, 1995
82. Bissada NK, Kaczmarek AT: Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol. J Urol 153:1944-1945, 1995
83. Akakura K, Akimoto S, Furuya Y, et al: Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur Urol 33:567-571, 1998
84. Schellhammer PF, Sharifi R, Block NL, et al: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45:745-752, 1995
85. Cox RL, Crawford ED: Estrogens in the treatment of prostate cancer. J Urol 154:1991-1998, 1995
86. Drago JR, Santen RJ, Lipton A, et al: Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53:1447-1450, 1984
87. Trump DL, Havlin KH, Messing ED, et al: High-dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologic and clinical effects. J Clin Oncol 7:1093-1098, 1989
88. O'Donnell A, Judson I, Dowsett M, et al: Hormonal impact of the 17alpha-hydroxylase/ C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90:2317-2325, 2004
89. Leroux F: Inhibition of p450 17 as a new strategy for the treatment of prostate cancer. Curr Med Chem 12:1623-1629, 2005
90. Lin DY, Fang HI, Ma AH, et al: Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol 24:10529-10541, 2004
91. Eder IE, Culig Z, Ramoner R, et al: Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7:997-1007, 2000
92. Zegarra-Moro OL, Schmidt LJ, Huang H, et al: Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62:1008-1013, 2002
93. Ko YJ, Devi GR, London CA, et al: Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. J Urol 172:1140-1144, 2004
94. Balana ME, Alvarez Roger C, Dugour AV, et al: Antiandrogen oligonucleotides: Active principles in hair- and skin-derived culture cells. J Drugs Dermatol 3:287-294, 2004
95. Chi KN, Cleave ME: Antisense approaches in prostate cancer. Expert Opin Biol Ther 4:927-936, 2004
96. Grenert J, Sullivan W, Fadden P, et al: The amino-terminal domain of heat shock protein (hsp90) that binds geldanamycin is an ATP/ADP switch that regulates hsp90 conformation. J Biol Chem 272:23843-23850, 1997
97. Stebbins CE, Russo AA, Schneider C, et al: Crystal structure of an Hsp90-geldanamycin complex: Targeting of a proetin chaperone by an antitumor agent. Cell 89:239-250, 1997
98. Solit DB, Scher HI, Rosen N: Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709-716, 2003
99. Scher HI, Solit DB, Munster PN, et al: Phase I trial of 17AAG (17-allylamino) 17-demethoxygeldanamycin (17AAG) in patients (Pts) with advanced cancer., Molecular Targets and Cancer Therapeutics: Discovery, biology, and clinical applications. Clin Cancer Res 7:3712s, 2001 (abstr 292)
100. Goetz MP, Toft D, Reid J, et al: Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087, 2005
101. Banerji U, O'Donnell A, Scurr M, et al: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152-4161, 2005
102. Grem JL, Morrison G, Guo XD, et al: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893, 2005
103. Bohl CE, Gao W, Miller DD, et al: Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci U S A 102:6201-6206, 2005
104. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170, 2000
105. Bramlett KS, Dits NF, Sui X, et al: Repression of androgen-regulated gene expression by dominant negative androgen receptors. Mol Cell Endocrinol 183:19-28, 2001
106. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
107. Chen L, Meng S, Wang H, et al: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4:1311-1319, 2005
108. Gore SD, Carducci MA: Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin Investig Drugs 9:2923-2934, 2000
109. Carducci MA, Gilbert J, Bowling MK, et al: A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047-3055, 2001
110. Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deactylase inhibitor: suberylanilide hydroxamic acid (SAHA) administered intravenously. Clin Cancer Res 9:3578-3588, 2003
111. Slovin SF, Kelly WK, Cohen R, et al: Epidermal growth factor receptor (EGFr) monoclonal antibody (MoAb) C225 and doxorubicin (DOC) in androgen-independent (AI) prostate cancer (PC): Results of a phase Ib/IIa study. Proc Amer Soc Clin One 16:311, 1997 (abstr 1108)
112. Agus D, Akita R, Fox W, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
113. Rosenthal M, Toner GC, Gurney H, et al: Inhibition of the epidermal growth factor receptor (EGFR) in hormone refractory prostate cancer (HRPC): Initial results of a phase II trial of gefitinib. Proc Am Soc Clin Oncol 22:416, 2003 (abstr 1671)
114. Tolcher AW: Novel therapeutic molecular targets for prostate cancer: The mTOR signaling pathway and epidermal growth factor receptor. J Urol 171:S41-44, 2004
115. Bianco R, Shin I, Ritter CA, et al: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822, 2003
116. She QB, Solit D, Basso A, et al: Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 9:4340-4346, 2003
117. Solit DB, She Y, Lobo J, et al: Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 11:1983-1989, 2005
118. Solit DB, Egorin M, Valentin G, et al: Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeladanamycin). J Clin Oncol 22:203, 2004 (suppl; abstr 3032)
119. Solit DB, Basso AD, Olshen AB, et al: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 63:2139-2144, 2003
120. Fox WD, Higgins B, Maiese KM, et al: Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 8:3226-3231, 2002
121. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004
122. Smith-Jones PM, Scher H, Larson SM, et al: HER2 imaging as a non-invasive pharmacodynamic marker of Hsp90 inhibition. 12th SPORE Investigators' Workshop, Baltimore, MD, July 10-13, 2004
123. Larson SM, Morris M, Gunther I, et al: Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 45:366-373, 2004
124. Beekman K, Morris M, Slovin S, et al: Androgen deprivation for minimal metastatic disease: The threshold for achieving an undetectable prostate-specific antigen. Urology 65:947-952, 2005
125. Scher HI, Morris MJ, Kelly WK, et al: Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11:5223-32, 2005